- 期刊
Comparison between Exclusive and Selective Drug-Eluting Stent Strategies in Treating Patients with Multivessel Coronary Artery Disease
並列摘要
Background: The expanded usage of drug-eluting stents (DES) in treating patients with multivessel coronary artery disease (CAD) may sometimes be limited in real-world practice due to cost concerns. We compared the clinical outcomes of exclusive and selective DES use in treating patients with multivessel CAD. Methods: From November 2004 to December 2011,110 patients with multivessel CAD who received four or more stents were enrolled into this study, and divided into two groups according to the DES strategy employed: exclusive DES (n = 52), or selective DES (n = 58). In the selective DES group, DES was reserved for complex lesions only, such that the incidence and predictors of clinical events were assessed. Results: At a mean follow-up of 41.4 ± 26.5 months, there were no significant differences between the two strategies in terms of baseline characteristics, all-cause mortality (exclusive vs. selective: 1.9% vs. 6.9%, p = 0.21), cardiac death (1.9% vs. 1.7%, p = 0.94) and nonfatal myocardial infarction (3.8% vs. 5.2%, p = 0.74). Despite the presence of more ostial lesions in the exclusive DES group, there was a trend such that major adverse cardiac events (MACE) and target lesion revascularization (TLR) rates were higher in the selective DES group (MACE: 17.3% vs. 31%, p = 0.16; TLR: 11.5% vs. 24.1%, p = 0.08). The higher MACE rate in the selective DES group was mainly driven by a higher target vessel revascularization (TVR) rate (15.4% vs. 29.3%, P = 0.08). In the exclusive DES group, SYNTAX score was an independent predictor of MACE [Haxard ratio (HR): 1.09, 95% confidence internal (CI): 1.02-1.16, p = 0.01] and TVR (HR 1.08, 95% CI1.01-1.15, P = 0.04). Conclusions: Compared to the exclusive DES strategy, the selective DES strategy with reservation of DES for complex lesions is associated with numerically higher, but not statistically significant, rates of MACE and all-cause mortality in this small group of patients with multivessel CAD receiving four or more stents.
延伸閱讀
- 林宜玲（2006）。Resources Utilization and Clinical Outcomes of Drug-Eluting Stent versus Bare Metal Stent in Coronary Artery Disease Patients〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-0407200616133200
- Panchal, K., Patel, S., & Bhatt, P. (2012). Drug-Eluting Stents in Multivessel Coronary Artery Disease: Cost Effectiveness and Clinical Outcomes. Advances in Pharmacological Sciences, 2012(), 162-167. https://doi.org/10.1155/2012/679013
- Tsai, M. L., Hsieh, M. J., Chen, C. C., Chang, S. H., Wang, C. Y., Chen, D. Y., Yang, C. H., Yeh, J. K., Ho, M. Y., & Hsieh, I. C. (2020). Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. Acta Cardiologica Sinica, 36(2), 97-104. https://doi.org/10.6515/ACS.202003_36(2).20190729A
- Liu, H. B., Guo, X. F., Wang, C. M., Jie, Y., Chen, G. Z., Zhang, L. M., Yong, C., Yu, F., Bao, Y. C., Yu, W. J., & Ge, J. B. (2014). Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation. Mediators of Inflammation, (2014-9), 459-465. https://doi.org/10.1155/2014/963096
- Sung, S. H., Chen, T. C., Cheng, H. M., Lee, J. C., Lang, H. C., & Chen, C. H. (2017). Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiologica Sinica, 33(1), 10-19. https://doi.org/10.6515/ACS20160608A